Head-to-head evidence
Depemokimab vs SB-240563
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: IL-5 · full Asthma pipeline
Depemokimab
Marketed by GlaxoSmithKline
NCT04718389 · Phase 3 · completed
This was a large randomized, double-blind, active-controlled trial comparing depemokimab with mepolizumab or benralizumab, using the clinically meaningful primary endpoint of annualized clinically significant asthma exacerbations. The primary results were 0.57 versus 0.49 exacerbations per participant-year (rate ratio 1.16, 95% CI 0.98–1.38; p=0.079), but the record does not provide the non-inferiority margin, so it is not possible to confirm that the primary endpoint was met.
Next expected readout: February 2027 · NCT07828327 (registry estimate)
SB-240563
Marketed by GlaxoSmithKline
NCT00292877 · Phase 2 · completed
The study randomized and double-blinded 20 participants for comparison with placebo, using a clinical primary endpoint based on prednisone reduction without clinical exacerbation. Because the registry contains no results, it is not possible to determine whether the primary endpoint was met; the small sample also limits the strength of the evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Depemokimab's landscape · SB-240563's landscape